NCT05785481

Brief Summary

This is a multicenter prospective observational study that aims to determine the natural history of patients with early diagnosis (within 6 hours of life) of mild hipoxic ischemic encephalopaty (HIE), who are not candidates for treatment with therapeutic hypothermia. The goal of this study is to learn about the early neurological outcome in babies with mild encephalopathy, as recent studies have shown how there is an increased risk of brain damage with a high incidence of resonance magnetic nuclear (RMN) anomalies and possible neurodevelopmental complications including learning or neuropsychological disorders, epilepsy, visual and sensory deficits. The main question aimed to answer is the identification of early possible predictive factors for an unfavorable outcome in order to undertake early rehabilitation programs and for the future planning of trials on early neuroprotection in the investigated population. Babies with early diagnosis (within 6h of life) of mild grade HIE not candidate for hypothermic treatment are subjected to clinical and instrumental assessments during the neonatal period:

  • neurological objective exam according to the modified "Sarnat" score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation;
  • an Amplitude Electroencephalogram (aEEG) study within 6 hours of life, for 6 hours;
  • cerebral ultrasound within 6 hours of life, in the third and seventh day of life;
  • a brain magnetic resonance imaging study between the seventh and 14th day of life;
  • an Electroencephalogram (EEG) evaluation within 7 days. After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:
  • Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements;
  • evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month;
  • EEG evaluation at the 6th and 12th month.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
27

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 27, 2020

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 7, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 2, 2023

Completed
25 days until next milestone

First Posted

Study publicly available on registry

March 27, 2023

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

March 27, 2023

Status Verified

March 1, 2023

Enrollment Period

2.7 years

First QC Date

March 2, 2023

Last Update Submit

March 14, 2023

Conditions

Keywords

Mild Hypoxic Encephalopathy

Outcome Measures

Primary Outcomes (6)

  • early neurological outcome

    the percentage of patients with mild asphyxia with evidence of brain damage, defined by MRI

    between the seventh and 14th day of life

  • early neurological outcome

    the percentage of patients with mild asphyxia with evidence of brain damage, defined by EEG abnormalities

    at the 6th month

  • early neurological outcome

    the percentage of patients with mild asphyxia with evidence of brain damage, defined by EEG abnormalities

    at 12th month.

  • early neurological outcome

    the percentage of patients with mild asphyxia with evidence of brain damage, defined by neurological examination

    at the 3th month

  • early neurological outcome

    the percentage of patients with mild asphyxia with evidence of brain damage, defined by neurological examination

    at the 6th month.

  • early neurological outcome

    the percentage of patients with mild asphyxia with evidence of brain damage, defined by neurological examination

    at the 12th month.

Secondary Outcomes (4)

  • Electroencephalographic and epilepsy outcome

    between the 6 hours of life and 12th month.

  • Neurodevelopmental outcome

    12th month

  • Hospitalization

    between birth until 12th month

  • adverse events

    between birth until 12th month

Study Arms (1)

Patients with early diagnosis (within 6 hours of life) of mild HIE

Diagnostic Test: Clinical and instrumental neurological assessment

Interventions

During the neonatal period: neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days. After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age: Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month.

Patients with early diagnosis (within 6 hours of life) of mild HIE

Eligibility Criteria

Age10 Minutes - 6 Hours
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

patients with early diagnosis (within 6 hours of life) of mild HIE, who are not candidates for treatment with therapeutic hypothermia

You may qualify if:

  • patients born after the 36th week of gestational age, with signs of encephalopathy found between the 10th minute of life and 6h, presenting with one or more of the following signs of intrapartum hypoxia with a potential of hydrogeb (pH) ≤ 7 or an excess of bases (BE) ≥ 12 mmol/l in the first hour of life, measured on cord or arterial blood or an abnormal course of delivery (eg: fetal heart rate abnormalities, cord prolapse, uterine tear, haemorrhage/ trauma/ convulsive seizures/ maternal cardiorespiratory arrest; shoulder dystocia; meconium-dyed amniotic fluid or protracted second stage and the presence of an Apgar at 10 min ≤5 or the need for continuous respiratory support at 10 minutes.

You may not qualify if:

  • mutes neurological objectivity;
  • impossibility of recruitment within 6h;
  • major congenital anomalies, brain malformations;
  • neonatal abstinence syndrome;
  • metabolic encephalopathies and severe growth restriction (birth weight ≤1800g);
  • treatment with therapeutic hypothermia;
  • refusal of consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione Policlinico Universitario Agostino Gemelli -IRRCS

Rome, 00168, Italy

Location

MeSH Terms

Conditions

Hypoxia, Brain

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypoxiaSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Domenico M Romeo, MD,PHD

    ChatolicUIT

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor, Principal investigator

Study Record Dates

First Submitted

March 2, 2023

First Posted

March 27, 2023

Study Start

February 27, 2020

Primary Completion

November 7, 2022

Study Completion

December 31, 2024

Last Updated

March 27, 2023

Record last verified: 2023-03

Locations